Access cutting-edge heart attack treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access heart attack specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heart attack treatment provided free
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Sponsor: Janssen Research & Development, LLC
Check if you qualify for this heart attack clinical trial in Birmingham, AL
If you're searching for heart attack treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart attack specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.